Biostatistician II- fully remote!
Thermo Fisher ScientificFull Time
Mid-level (3 to 4 years), Senior (5 to 8 years)
Cambridge, Massachusetts, United States
Key technologies and capabilities for this role
Common questions about this position
A PhD in Statistics/Biostatistics, Mathematics, or related quantitative fields with at least 10 years of experience in clinical trials including late-phase studies is required, or an MSc with a minimum of 14 years of such experience. Proficiency in scientific computing/programming (SAS or R) and implementation of advanced statistical analyses and simulations, along with deep knowledge of CDISC standards, is also required.
The role is based in Cambridge, Massachusetts, and involves occasional travel to Cambridge, MA and other locations for collaboration and conferences, typically at least three times annually.
Amylyx's core values are to be audacious, be curious, be authentic, be engaged, and be accountable, creating a culture of caring. The company has assembled an experienced team ready to take action with urgency, rigorous science, and commitment to the communities they serve.
This information is not specified in the job description.
Candidates with a PhD (10+ years) or MSc (14+ years) in relevant quantitative fields, proficiency in SAS or R, advanced statistical analyses experience in late-phase clinical trials, and deep CDISC knowledge will stand out, especially with leadership in clinical development programs.
Develops treatments for neurodegenerative diseases
Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes and enhance the quality of life for individuals suffering from neurodegenerative conditions.